News | May 05, 2026
SK Capital sells Noramco assets to Siegfried
Keeps Halo Pharma to drive independent growth
Keeps Halo Pharma to drive independent growth
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
Subscribe To Our Newsletter & Stay Updated
